TY  - JOUR
AB  - The chairman and CEO of the Genzyme Corporation, one of the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.
VL  - 
IS  - 
SN  - 2474-7890
DO  - 10.1108/case.darden.2016.000132
UR  - https://doi.org/10.1108/case.darden.2016.000132
AU  - Eades Kenneth M.
AU  - Matos Pedro
AU  - Green Rick
PY  - 2017
Y1  - 2017/01/01
TI  - Genzyme and Relational Investors: Science and Business Collide?
T2  - Darden Business Publishing Cases
PB  - University of Virginia Darden School Foundation
SP  - 1
EP  - 25
Y2  - 2024/04/26
ER  -